MEN1112 is the first monoclonal antibody to be developed in the collaboration between Menarini and OBT (Oxford BioTherapeutics).
MEN 1112 is a humanized de-fucosylated monoclonal IgG1 antibody that acts through an ADCC (Antibody-Dependent Cellular Toxicity) mechanism of action.
The target of MEN1112 is CD157, a protein over expressed in patient blasts who have acute myeloid leukemia (AML): data showing antitumor effects on cancer cell lines and on leukemic blasts from patients have been obtained.
The biotechenological process for the production of MEN1112 has been developed at Menarini Biotech in Pomezia.
The first in human study in patients with relapsed/refractory acute myeloid leukemia (clinical study ARMY) is ongoing
VISIT OUR CLINICAL TRIALS DATABASE